Revlar Diagnostics

Revlar Diagnostics is a biotechnology and healthcare startup based in the United States, founded in 2019. The company's slogan, "Developing breakthrough infectious disease diagnostic solutions designed for speed, sensitivity, and simplicity," encapsulates its mission. Revlar Labs aims to revolutionize infectious disease diagnostics in both commercial and laboratory markets. Their approach includes Covid-targeted assays utilizing patented biosensors in vitro, as well as on-site and Point of Care diagnostic solutions. The company's offerings address the challenges associated with typical PCR and rapid antigen tests for COVID. By leveraging hinged peptid molecular nanoswitches, Revlar Labs has designed a better diagnostic solution that promises speed, simplicity, and sensitivity, enabling labs to scale accurate, rapid-results tests. Their CLIA LAB solutions encompass Covid-targeted assay development and High-Throughput Lab (HTL) kits. Additionally, they provide on-site Covid solutions suitable for Point of Care providers, venues, employers, and school campuses. Revlar Diagnostics presents an innovative and timely solution to the pressing need for reliable and efficient infectious disease diagnostics. Their focus on scalability, accuracy, and speed makes them a promising player in the biotechnology and healthcare industries. As of now, there's no publicly available information about their last investment, investors, or investment amount. For potential investors seeking opportunities in the infectious disease diagnostics space, Revlar Diagnostics could be an intriguing prospect. For further information, interested parties can reach out to Tony via [email protected] .